Original language | English (US) |
---|---|
Journal | Pediatric pulmonology |
DOIs | |
State | Accepted/In press - 2020 |
Keywords
- biography
- cystic fibrosis
- lung function
- pediatric pulmonology
- pulmonary exacerbations
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Pulmonary and Respiratory Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Pediatric pulmonology, 2020.
Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - Dr Jeffrey S. Wagener
T2 - An impactful career and life
AU - Deterding, Robin R.
AU - Morgan, Wayne J.
N1 - Funding Information: Robin R. Deterding MD Wayne J. Morgan MD, CM [email protected] University of Colorado School of Medicine Aurora Colorado The University of Arizona College of Medicine Tucson Arizona biography cystic fibrosis lung function pediatric pulmonology pulmonary exacerbations we hope to recognize Jeff's contributions and inspire others by his example. Dr Jeffrey S. Wagener passed away in October of 2018, but he left an indelible mark on the field of Pediatric Pulmonary Medicine, Cystic Fibrosis, colleagues, trainees and patients around the world. Through these comments accompanying his last publication, Dr Wagener was Professor in the Department of Pediatrics at the University of Colorado School of Medicine. He earned his medical degree from the University of Colorado in 1975, completed residency in Pediatrics at the University of Washington in Seattle in 1978, and fellowship in Pediatric Pulmonary Medicine at the University of Arizona in Tucson in 1980. Before returning to Colorado to join the faculty in 1990, Dr Wagener was on the faculty at the University of Iowa and was Director of the Pediatric Intensive Care unit. He also had a passion for connecting internationally as he was a lecturer in University of Melbourne, Melbourne, Australia and completed sabbaticals in Christchurch School of Medicine, Christchurch, New Zealand and Children's University Hospital, Dublin, Ireland. During Dr Wagener's 28 years in Colorado, he served in many roles. He was the Director of Pulmonary Medicine Services at the Children's Hospital Colorado, Pediatric Pulmonary Fellowship Director and Cystic Fibrosis Associate Director Cystic Fibrosis Center. Jeff prided himself most in his love for teaching. He was an exceptional clinical educator who focused on clinical science with a rigorous, evidence‐based approach to care. Trainees were his passion and he trained many pediatric pulmonary fellows, both in Colorado and through his work with the American Thoracic Society and the Cystic Fibrosis Foundation. Many of these trainees are now Division Chiefs and/or leaders in our field. Jeff was recognized for this study with the Outstanding Clinician Award by the American Thoracic Society and a Career Teaching Scholar Award from the Department of Pediatrics at the University of Colorado. As a clinical scholar, Wagener participated in 38 clinical trials focused on inhaled antibiotics and markers of airway inflammation, published over 150 different types of publications, and was an ad hoc reviewer for many professional journals. Jeff also served on the Cystic Fibrosis Foundation (CFF) Center Committee and on the Pediatric Advisory and Pulmonary‐Allergy Drug Advisory Committees of the FDA. an analysis of changes in lung function in ESCF participants before and after pulmonary exacerbations (PEx) treated with antimicrobials. Lung function decline often plays a key role in PEx diagnosis and the recovery of percent predicted FEV Jeff's major scholarly work focused on cystic fibrosis (CF) where he had a significant impact on CF care. He pursued CF research projects ranging from coagulation problems, to infant lung function testing, to detection of airway inflammation. He was among the first to show that early airway inflammation occurred in CF, thus underscoring the importance of early treatment. After joining Dr Accurso at the University of Colorado, Jeff became a major advocate of newborn screening so that treatment could be started before CF complications occurred. With early identification came the opportunity to apply new technologies to early detection of lung disease. Along with Drs Khan and Accurso, Jeff conducted the first studies of bronchoscopy in infants with CF. This led to the first national study using bronchoscopy to demonstrate the delivery of inhaled medication into the lungs of young children. Jeff was also interested in antioxidants and performed several studies of vitamin use in CF. He was a key member of the Epidemiologic Study of Cystic Fibrosis (ESCF) Scientific Advisory Group where his rigor and ability to challenge the received knowledge in our field played a key role in a number of publications characterizing trends in CF and CF care patterns and their outcomes in the United States. He was also a strong advocate for the use of the Cystic Fibrosis Quality of Life questionnaire in the ESCF and in understanding how clinicians managed patients with cystic fibrosis in the real‐world setting of an observational study. Jeff always brought a keen intellect and a rigorous approach to the work in ESCF that materially improved the science in this observational study. He had a particular interest in characterizing pulmonary exacerbations (PEx) in cystic fibrosis and their impact on patient outcomes. In this issue, Jeff reports 1 (ppFEV 1 ) to a prior “baseline value” is commonly used to assess treatment response. In this paper, greater ppFEV 1 decline was associated with a lower rate of recovery to baseline and disturbingly only 28% of all PEx treatments resulted in complete recovery over a 6 month follow‐up period. Further, among the 10% of PEx presenting with no apparent decline in lung function, more than one‐third had a decreased ppFEV 1 during follow‐up with risk factors for this outcome being similar to those predicting lack of recovery in those who demonstrated a PEx related drop in ppFEV 1 . The results of this study suggest that intraindividual ppFEV 1 variability, regression to the mean, sampling methodologies, and underlying lung disease progression materially complicate the commonly used “return to baseline” approach when assessing the impact of PEx and treatment response on lung function outcome. Jeff's paper challenges both CF clinicians and scientists to better understand how to analyze lung function change in relation to PEx in both clinical practice and observational studies. Dr Wagener's interest in clinical research derived from his deep commitment to his patients and their families. He was beloved by his patients for his compassionate care and he both practiced and taught patient‐centered care. He was active in outreach clinics in Colorado Springs, Billings, MT, and Great Falls, MT. Nationally he served on the CF Foundation's Center Committee, which is responsible for evaluating and making recommendations to the over 100 CF Centers throughout the United States. Jeff was active on the local CFF board for over a decade. Dr Wagener was one of the leading CF clinicians, researchers, and educators in the country and clearly excelled as a clinical scholar. Finally, there were unique aspects to Jeff that were “just Jeff.” He delighted in “the question,” finding the answers and encouraging his trainees to do the same. Words frequently used to describe Jeff from colleagues and trainees included passionate advocacy, generosity, curiosity, excellence in clinical care and mentorship. He balanced his work life with a love of family, being outdoors and encouraged fellows to do the same. His career and life were well lived. Thank you, Jeff, for all you gave to so many.
PY - 2020
Y1 - 2020
KW - biography
KW - cystic fibrosis
KW - lung function
KW - pediatric pulmonology
KW - pulmonary exacerbations
UR - http://www.scopus.com/inward/record.url?scp=85078599257&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078599257&partnerID=8YFLogxK
U2 - 10.1002/ppul.24642
DO - 10.1002/ppul.24642
M3 - Editorial
C2 - 31951079
AN - SCOPUS:85078599257
SN - 8755-6863
JO - Pediatric pulmonology
JF - Pediatric pulmonology
ER -